Proceedings - Boulder Peptide Foundation

BPS 2025

Clinical Development of a PSD-95 Inhibitor for Acute Ischemic Stroke

Corey Adams

Chief Business Officer, NoNO Inc.

ABSTRACT

NoNO Inc. is developing emergency stroke treatments and has demonstrated clinical proof of concept for the in-hospital use of the eicosapeptide nerinetide to improve outcomes for acute ischemic stroke (AIS) patients. Even with the best currently available treatments, at 3 months post-stroke approximately 15% of acute ischemic stroke patients still die, half lose functional independence and more than 80% have residual functional deficits. The global burden of disease for stroke is 2-4 times that of all dementias combined (for mortality and disability adjusted life years, respectively, including Alzheimer’s) and is the second leading cause of death globally. NoNO has conducted three large, randomized, placebo-controlled trials (FRONTIER, ESCAPE-NA1 and ESCAPE-NEXT) demonstrating clinical proof of concept that nerinetide, a first-in-class PSD-95 inhibitor, can ‘help the brain hold its breath’ long enough for blood flow to be restored and improve outcomes. The results underscore the critical importance of rapid treatment – as soon as possible and at least within 3 hours of stroke onset – to improve outcomes for the 12.2 million annual cases and 101.5 million people living in the aftermath of stroke globally.

BIO

Dr. Adams joined NoNO Inc. in 2017 bringing 20 years of operational experience in drug discovery and development, strategic partnering and global pharmaceutical transactions with a particular focus on the Central Nervous System (CNS). Dr. Adams leads the company’s financial, intellectual property and partnering functions. He began his career in the Department of Neurology at Boston Medical Center supporting a broad portfolio of CNS disease research focused primarily on neurodegeneration. He completed his PhD in Pharmacogenomics at the University of California San Francisco where he also served as Executive Director of the UCSF Innovation Accelerator spinning out technologies and companies from the University. Dr. Adams spent the next decade in business development roles incubating new ventures and leading transactions for both small biotech and specialty pharma.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.